Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Portable, Handheld COVID-19 Test Produces Laboratory-Quality Results within 15 Minutes in Any Setting

By HospiMedica International staff writers
Posted on 12 Feb 2021
A portable, handheld test produces laboratory-quality results in 15 minutes in any setting to increase access and availability of COVID-19 testing.

Nanomix, Inc. More...
(Emeryville, CA, USA) has submitted an Emergency Use Authorization request to the US Food and Drug Administration (FDA) for the eLab COVID-19 rapid antigen test. The assay runs on the portable Nanomix eLab analyzer, which provides results in just 15 minutes and can be used in a wide range of settings, including hospitals, nursing homes, assisted living facilities, urgent care centers, and emergency medical care. The fully automated point-of-care Nanomix eLab platform consists of a handheld reader and an integrated, self-contained assay cartridge with a proprietary biosensor. The system weighs two pounds, and is about the size of a brick.

The device is simple to operate via an intuitive user interface on a color touch screen. All test functions are controlled and automatically processed by the device. Results are available on the screen, via Bluetooth, or a connected printer. The robust design supports the system’s use in almost any setting, inside or outside of the traditional laboratory environment. The Nanomix eLab platform uses a proprietary nano-biosensor formatted into a disposable microfluidics test cartridge for high-quality, reliable performance.

The Nanomix eLab platform and COVID-19 rapid antigen test will enable medical professionals, emergency workers, and employers to test individuals for antigens that indicate COVID-19 infection. The assay uses a nasal swab sample that can be self-administered, and is designed to complement existing test methods by expanding access to rapid, laboratory-quality results outside of hospital facilities.

“While the global healthcare community has made tremendous progress in COVID-19 testing, there is still significant need for rapid, accurate, and affordable testing that can be conducted outside of laboratory settings,” said David Ludvigson, president and CEO of Nanomix. “By completing this EUA filing, we are one step closer to making our antigen test available to help address this remaining gap.”

Related Links:
Nanomix, Inc.


New
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Radiofrequency Generator
GX1
New
Medical-Grade Display
HL2316SHTB
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.